Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cryptic family protein 1B (CFC1B)
- Target
- CFC1B
- Molecular classification
- EGF-CFC family protein, Glycosylphosphatidylinositol (GPI)-anchored co-receptor, Membrane-associated signaling protein
01
Overview
Cryptic family protein 1B (CFC1B) belongs to the EGF-CFC (Cripto/FRL-1/Cryptic) family of signaling proteins. It is a GPI-anchored co-receptor with a cysteine-rich EGF-like domain, essential for patterning the left-right axis during embryonic development. CFC1B interacts with the Nodal and Activin type I receptor ALK4, contributing to circulation, organ morphogenesis, and stem cell fate specification. It is overexpressed in multiple cancers, promotes epithelial-to-mesenchymal transition (EMT), and has been linked to poor survival and tumor aggressiveness. Mutations or dysregulation are associated with congenital disorders such as visceral heterotaxy and heart defects.
- Other names
- CriptoFRL-1CrypticHTX2DTGA2Cryptic family protein 1BCFC1B
02
Mechanism of action
Not established, as direct pharmacological targeting data is currently unavailable. Theoretical mechanisms would involve modulation of embryonic signaling, Nodal/Activin interaction, and EMT if a selective drug were developed.
03
Biological functions
Co-receptor for Nodal signalingActivin receptor bindingEmbryonic development patterning (left-right axis)Cell signaling regulationPromotion of epithelial-to-mesenchymal transition (EMT)Cell proliferationCardiac and organ morphogenesisStem cell fate regulation
04
Disease associations
Cancer (pancreatic, breast, colon, colorectal, gastric)Congenital heart diseaseVisceral heterotaxyTetralogy of FallotAutosomal organ developmental defectsMethylmalonic aciduria with homocystinuriaDyschromatosis symmetrica hereditaria
05
Safety considerations
Developmental toxicity: Essential in embryogenesis; inhibition may lead to developmental defectsOncogenic risk: Overexpression associated with various cancers; safety concerns would include potential off-target oncogenic effectsCardiac and organ malformation risks: Disruption during development can cause congenital defects
06
Biomarkers
Cancer stem cell marker (Cripto-1, closely related to CFC1B, is proposed as a marker in oncology)Cripto expression levels (linked to resistance to EGFR inhibitors and poor prognosis in cancers)
Beyond the preview
Go deeper on Cryptic family protein 1B (CFC1B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cryptic family protein 1B (CFC1B).